


CLAIMS

What is claimed is:

1. An enantiomerically pure compound of Formula 3:



Formula 3

- 5 or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, wherein: X is O or NR₃; R₁ and R₁' are both H or when taken together are =O; R₂ and R₂' are both H or when taken together are =O; and R₃ is H, alkyl, aryl, arylalkyl or -COR₄, wherein R₄ is H, amine, alkyl, alkoxy, aryl, aryloxy, arylalkyl, or O-arylalkyl; provided that when X is NR₃ and R₁, R₁', R₂, and R₂' are all H, then R₃ is not H or methyl.
- 10

2. The compound of claim 1 wherein X is NR₃ and R₁ and R₁' are both H.

3. The compound of claim 2 wherein R₂ and R₂' are taken together to be =O.

15

4. The compound of claim 1 wherein X is NR₃ and R₁ and R₁' are taken together to be =O and R₂ and R₂' are taken together to be =O.


5. The compound of claim 1 wherein X is NR₃ and R₁, R₁', R₂, and R₂' are all H and R₃ is -COR₄, wherein R₄ is H, alkyl, NH₂, or alkoxyalkyl.
- 20

6. The compound of claim 5 wherein R₄ is H, CH₃, NH₂ or -OCH₂CH₃.


7. The compound of claim 1, wherein X is O and R₁, R₁', R₂ and R₂' are all H.

25


8. A compound selected from the following:




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,



,




,



,

or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.

9. A pharmaceutical composition comprising a compound of Formula 3:




Formula 3

- 5 or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, wherein: X is O or NR₃; R₁ and R₁' are both H or when taken together are =O; R₂ and R₂' are both H or when taken together are =O; and R₃ is H, alkyl, aryl, arylalkyl or -COR₄, wherein R₄ is H, amine, alkyl, alkoxy, aryl, aryloxy, arylalkyl, or O-arylalkyl; provided that when X is NR₃ and R₁, R₁', R₂, and R₂' are all H, then R₃ is not H or methyl; and a pharmaceutically
- 10 acceptable excipient.
10. The pharmaceutical composition of claim 9 wherein X is NR₃ and R₁ and R₁' are both H.
- 15 11. The pharmaceutical composition of claim 10 wherein R₂ and R₂' are taken together to be =O.
12. The pharmaceutical composition of claim 9 wherein X is NR₃ and R₁ and R₁' are taken together to be =O and R₂ and R₂' are taken together to be =O.
- 20 13. The pharmaceutical composition of claim 9 wherein X is NR₃ and R₁, R₁', R₂, and R₂' are all H and R₃ is -COR₄, wherein R₄ is H, alkyl, NH₂ or alkoxyalkyl.
14. The pharmaceutical composition of claim 13 wherein R₄ is H, CH₃, NH₂ or
- 25 -OCH₂CH₃.
15. The pharmaceutical composition of claim 9 wherein X is O and R₁, R₁', R₂ and R₂' are all H.

16. The pharmaceutical composition of claim 9 wherein the compound of Formula 3 is stereomerically pure.

17. A method of treating or preventing a disease or condition which is affected by the modulation of one or more central benzodiazepine sites in a patient which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of Formula 3:



Formula 3

18. or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, wherein: X is O or NR₃; R₁ and R₁' are both H or when taken together are =O; R₂ and R₂' are both H or when taken together are =O; and R₃ is H, alkyl, aryl, arylalkyl or -COR₄, wherein R₄ is H, amine, alkyl, alkoxy, aryl, aryloxy, arylalkyl, or O-arylalkyl; provided that when X is NR₃ and R₁, R₁', R₂, and R₂' are all H, then R₃ is not H or methyl.

15

18. The method of claim 17 wherein the disease or condition is anxiety, an affective disorder, a convulsive disorder, spasticity or acute muscle spasm, a behavioral disorder, or alcohol or drug addiction.


19. The method of claim 18 wherein the affective disorder is depression, attention deficit disorder, attention deficit disorder with hyperactivity, or attention deficit/hyperactivity disorder.

20. The method of claim 18 wherein the convulsive disorder is epilepsy.

25

21. The method of claim 18 wherein the behavioral disorder is mood anxiety or schizophrenia.

22. A method of treating or preventing drug withdrawal, alcohol withdrawal, symptoms of drug withdrawal, or symptoms of alcohol withdrawal in a patient which comprises administering to a patient in need of such treatment a therapeutically or prophylactically effective amount of a compound of Formula 3:



Formula 3

5 or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, wherein: X is O or NR₃; R₁ and R₁' are both H or when taken together are =O; R₂ and R₂' are both H or when taken together are =O; and R₃ is H, alkyl, aryl, arylalkyl or -COR₄, wherein R₄ is H, amine, alkyl, alkoxy, aryl, aryloxy, arylalkyl, or O-arylalkyl; provided that when X is NR₃ and R₁, R₁', R₂, and R₂' are all H, then R₃ is not H or methyl.

23. The method of claim 17 or 22 wherein the compound of Formula 3 is stereomerically pure.